Next Article in Journal
Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline
Previous Article in Journal
A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 4
10.3747/co.21.1966
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Guidelines

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

by
J. Boulanger
1,*,
J.N. Boursiquot
2,
G. Cournoyer
3,
J. Lemieux
4,
M.S. Masse
5,
K. Almanric
6,
M.P. Guay
7 and
1 the Comité de l’évolution des pratiques en oncologie
1
Institut national d’excellence en santé et services sociaux (inesss), Quebec City, QC, Canada
2
Centre hospitalier de l’Université Laval (chu de Québec), Quebec City, QC, Canada
3
Hôpital régional de Saint-Jérôme (csss de Saint-Jérôme), Saint-Jérôme, QC, Canada
4
Hôpital du Saint-Sacrement (chu de Québec), Quebec City, QC, Canada
5
‖Hôpital Notre-Dame (chum), Montreal, QC, Canada
6
Hôpital de la Cité-de-la-Santé (csss de Laval), Laval, QC, Canada
7
Jewish General Hospital, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(4), 630-641; https://doi.org/10.3747/co.21.1966
Submission received: 7 May 2014 / Revised: 2 June 2014 / Accepted: 9 July 2014 / Published: 1 August 2014

Abstract

(1) Background: Although antineoplastic agents are critical in the treatment of cancer, they can potentially cause hypersensitivity reactions that can have serious consequences. When such a reaction occurs, clinicians can either continue the treatment, at the risk of causing a severe or a potentially fatal anaphylactic reaction, or stop the treatment, although it might be the only one available. The objective of the present work was to evaluate the effectiveness of methods used to prevent and treat hypersensitivity reactions to platinum- or taxane-based chemotherapy and to develop evidence-based recommendations. (2) Methods: The scientific literature published to December 2013, inclusive, was reviewed. (3) Results: Premedication with antihistamines, H2 blockers, and corticosteroids is not effective in preventing hypersensitivity reactions to platinum salts. However, premedication significantly reduces the incidence of hypersensitivity to taxanes. A skin test can generally be performed to screen for patients at risk of developing a severe reaction to platinum salts in the presence of grade 1 or 2 reactions, but skin testing does not appear to be useful for taxanes. A desensitization protocol allows for re-administration of either platinum- or taxane-based chemotherapy to some patients without causing severe hypersensitivity reactions. (4) Conclusions: Several strategies such as premedication, skin testing, and desensitization protocols are available to potentially allow for administration of platinum- or taxane-based chemotherapy to patients who have had a hypersensitivity reaction and for whom no other treatment options are available. Considering the available evidence, the Comité de l’évolution des pratiques en oncologie made recommendations for clinical practice in Quebec.
Keywords: hypersensitivity reactions; taxanes; platinum salts; skin testing; desensitization; chemotherapy; management hypersensitivity reactions; taxanes; platinum salts; skin testing; desensitization; chemotherapy; management

Share and Cite

MDPI and ACS Style

Boulanger, J.; Boursiquot, J.N.; Cournoyer, G.; Lemieux, J.; Masse, M.S.; Almanric, K.; Guay, M.P.; , the Comité de l’évolution des pratiques en oncologie. Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations. Curr. Oncol. 2014, 21, 630-641. https://doi.org/10.3747/co.21.1966

AMA Style

Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, Guay MP, the Comité de l’évolution des pratiques en oncologie. Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations. Current Oncology. 2014; 21(4):630-641. https://doi.org/10.3747/co.21.1966

Chicago/Turabian Style

Boulanger, J., J.N. Boursiquot, G. Cournoyer, J. Lemieux, M.S. Masse, K. Almanric, M.P. Guay, and the Comité de l’évolution des pratiques en oncologie. 2014. "Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations" Current Oncology 21, no. 4: 630-641. https://doi.org/10.3747/co.21.1966

APA Style

Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., Masse, M. S., Almanric, K., Guay, M. P., & , the Comité de l’évolution des pratiques en oncologie. (2014). Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations. Current Oncology, 21(4), 630-641. https://doi.org/10.3747/co.21.1966

Article Metrics

Back to TopTop